Alzheimer’s disease (AD) is one of the most urgent global health challenges of our time. But here’s a startling fact: Postmenopausal Women are at a much higher risk of developing AD than men. Why? The answer, although complex, may in part lie at the intersection of HormonalDecline and BrainMetabolism during Menopause - a critical yet underexplored area of research.
🎓 Christopher O'Mahony, a brilliant former MSc student in BiomolecularScience at Science_Engineering UL, took on this challenge through exciting research. By analyzing TranscriptomicData from women at various life stages, including those affected by AD, he identified FOXO3 as a potential key player connecting Menopause and Neurodegeneration.
📢 As part of his MSc project, we wrote a review, presenting hypotheses on FOXO3’s metabolic contribution at the crossroads of menopause and AD. Our goal? To spark discussions and pave the way for innovative therapeutic approaches to addressing the heightened AD risk in women.
📖 Curious to learn more? Read the full article here: https://www.sciencedirect.com/science/article/pii/S0531556525000075
UL Research
Science_Engineering UL
Therapeutics #PrecisionMedicine AD Menopause MolecularMechanisms
